Skip to main content
BL Pharmtech Corp. logo

BL Pharmtech Corp. — Investor Relations & Filings

Ticker · 065170 ISIN · KR7065170003 KO Manufacturing
Open in API
Filings indexed 280 across all filing types
Latest filing 2026-06-15 Capital/Financing Update
Country KR South Korea
Listing KO 065170

About BL Pharmtech Corp.

http://www.blpharmtech.com/

BL Pharmtech Corp. is a healthcare company that manufactures, distributes, and sells health functional foods, dietary supplements, and nutraceuticals. The company's portfolio also includes cosmetics, food additives, and pharmaceuticals. A significant part of its operations is dedicated to biotechnology and bio-pharmaceutical research and development. Through its Daedeok Research Institute and in collaboration with subsidiaries BL Melanys and BL Science, the company partners with academic institutions, including KAIST and Columbia University Medical Center, to advance its research initiatives.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 95% confidence The document is titled '주요사항보고서(전환사채권 발행결정)', which translates to 'Major Information Report (Decision to Issue Convertible Bonds)'. It contains detailed information regarding the issuance of convertible bonds, including terms like interest rates, maturity, conversion prices, adjustment clauses, put and call options, and detailed tables of bond characteristics and investor information. The document is a notification of a financing decision, discussing bond issuance and terms rather than financial results or management commentary. There is no indication that this is a full financial report, audit report, or annual/interim report. It is clearly an update on capital raising via bond issuance and related financing details. According to the filing definitions, such updates on company fundraising and financing activities fall under Capital/Financing Update (Code: CAP). The document is substantive, over 13,000 characters, and detailed, not an announcement of a report publication, so it is not RPA. Hence, the correct classification is CAP with high confidence.
2026-06-15 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 87% confidence The document is titled “분기보고서” covering the period 2026-01-01 to 2026-03-31 (32nd fiscal period, Q1). It contains detailed financial statements, segment revenues, risk management disclosures, asset schedules, and extensive narrative of business operations—hallmarks of a full interim/quarterly report, not just an announcement or summary. Therefore, it fits the Interim/Quarterly Report category. Q1 2026
2026-05-15 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 95% confidence The document is a formal regulatory notice reporting the appointment (and related changes) of an outside director at a listed company. It details changes to the board of directors (사외이사의 신규선임), including names, dates, and terms. Such filings are classified under Board/Management Information.
2026-03-31 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document provides detailed results of an Annual General Meeting (정기주주총회결과), including approvals of financial statements, dividend resolutions, election of directors and auditors, and vote tallies with percentages for each agenda item. This corresponds exactly to a Declaration of Voting Results & Voting Rights Announcement rather than the report itself or a solicitation. Therefore, it should be classified as DVA.
2026-03-31 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the 31st fiscal year (2025) of BL Pharmtech Corp. It contains detailed company information, business operations, financial data, and management discussions. This is the standard Korean regulatory filing equivalent to an Annual Report (10-K). FY 2025
2026-03-24 Korean
감사보고서제출
Audit Report / Information Classification · 92% confidence The document is titled “감사보고서 제출” (Audit Report Submission) and includes detailed audit opinions for both consolidated and separate financial statements, showing unqualified opinions, key balance sheet and income statement figures, audit firm name, and submission date. This is not merely a brief notice of report publication but contains substantive audit report information. It matches the definition of a standalone Audit Report (AR). FY 2025
2026-03-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.